---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Mechanism of action"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Mechanism of action. Topics: Allosteric inhibition of TYK2 through the pseudokinase (JH2) domain; Cytokine pathways mediated by TYK2; Selectivity for TYK2 over JAK1, JAK2, and JAK3; Human whole-blood inhibitory concentrations by cytokine pathway; 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/mechanism-of-action"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Mechanism of action

<a id="heading-2.1.2.6.1"></a>

## 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

### Allosteric inhibition of TYK2 through the pseudokinase (JH2) domain

> “In contrast, allosteric TYK2 inhibitors such as envudeucitinib achieve selectivity by binding to the pseudokinase JAK homology 2 (JH2) domain, a regulatory site unique to TYK2”
> “This binding induces a conformational change that prevents the activation of the catalytic JH1 domain, thereby functionally blocking ATP binding and TYK2 signaling”
> “Because the TYK2 JH2 domain is structurally distinct from the JH2 domains of other JAK family members, this allosteric mechanism (indirect inhibition) confers high selectivity for TYK2, preserving JAK 1/2/3 activity and reducing the risk of adverse events associated with classic JAK inhibition”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

> “ESK‐001 is a highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2), which plays an essential role in mediating cytokine signaling in multiple immune‐mediated diseases.”
> “Here, we describe ESK‐001, an orally available and highly selective allosteric TYK2 inhibitor binding to the JH2 domain of TYK2, which is being developed for the treatment of plaque psoriasis, SLE, and other immune‐mediated diseases.”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-2.1.2.6.1-2"></a>

### Cytokine pathways mediated by TYK2

> “TYK2 mediates downstream signaling of IL-23 as well as other cytokines, including IL-12 and type I interferons (IFNs)”
> “Thus, inhibition of TYK2 provides comprehensive targeting that reduces both the signaling and production of the proinflammatory cytokines central to psoriasis pathogenesis.”
> “Inhibition of TYK2 reduces production and inflammatory signaling of cytokines associated with psoriasis without affecting cytokines involved in immune pathways, lipid metabolism, and blood cell development.”

Source: [Armstrong et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13237387/)

<a id="topic-2.1.2.6.1-3"></a>

### Selectivity for TYK2 over JAK1, JAK2, and JAK3

> “Due to envu’s design as an allosteric inhibitor, the molecule is both potent and intrinsically selective for TYK2 over other protein kinases, including the related JAK family members.”
> “No JAK-related pharmacology has been observed with envu to date.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

> “Preclinical studies showed that ESK‐001 was pharmacologically active and highly selective against TYK2 (50% inhibitory concentration [IC50] of 104–149 nM in human whole blood), and had no off‐target effects on other kinases (IC50 of >30,000 nM for JAK1‐3).”

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/)

<a id="topic-2.1.2.6.1-4"></a>

### Human whole-blood inhibitory concentrations by cytokine pathway

| Stimulus (kinase pathway) | Human whole blood IC50 (nM) |
| --- | --- |
| IFNα (TYK2) | “104” |
| IL-12 (TYK2) | “149” |
| IL-2 (JAK1/JAK3) | “>30,000” |
| TPO (JAK2) | “>30,000” |

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

<a id="topic-2.1.2.6.1-5"></a>

### Kinome selectivity and binding to the JH2 allosteric pocket

> “Exclusive binding of ESK-001 to the JH2 allosteric binding pocket avoids JAK kinase liabilities.”
> “Highly selective for TYK2: no off-target binding across kinome, no measurable JAK pharmacology.”
> “Only 2 of 468 kinases inhibited”
> “JAK1 JH2 domain (no functional consequence)”

Source: [Ucpinar et al. (2024a)](https://www.alumis.com/file.cfm/18/docs/alumis_pub_3_aad_poster_2024.pdf)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
